PDCD1 and cancer: Interestingly, a similar survival pattern is observed in a small cohort of patients with uveal melanoma (Fig. 2b), one of the types of cancer that is most refractory to anti-PD-1 and anti-CTLA-4 blockade.66 Moreover, analysis of STAB1 among all immunotherapy-treated patients from The Cancer Genome Atlas pan-cancer data, including anti-CTLA-4-treated cases and two PD-1 blockade cohorts,67,68 shows that STAB1 expression is, indeed, significantly higher among the non-responding patients than the responders (Fig. 2c).